Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1994 Jan;39(1):1–14. doi: 10.1007/BF01517174

Relevance of the T cell receptor for immunotherapy of cancer

Eckhart Weidmann 1, Massimo Trucco 2, Theresa L Whiteside 3,4,✉
PMCID: PMC11038863  PMID: 8044821

The content is available as a PDF (1.8 MB).

Footnotes

This manuscript was supported in part by the Pathology Education and Research Foundation

References

  • 1.Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst. 1991;83:932. doi: 10.1093/jnci/83.13.932. [DOI] [PubMed] [Google Scholar]
  • 2.Alt FW, Oltz EM, Young F, Gorman J, Taccioli G, Chen J. VDJ recombination. Immunol Today. 1992;13:306. doi: 10.1016/0167-5699(92)90043-7. [DOI] [PubMed] [Google Scholar]
  • 3.Anichini A, Fossati G, Parmiani G. Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma. Int J Cancer. 1985;35:683. doi: 10.1002/ijc.2910350518. [DOI] [PubMed] [Google Scholar]
  • 4.Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H. Home therapy with recombinant interleukin 2 and interferon alpha 2b in advanced human malignancies. Lancet. 1990;335:1509. doi: 10.1016/0140-6736(90)93039-r. [DOI] [PubMed] [Google Scholar]
  • 5.Aulitsky W, Gastl G, Aulitsky WE, Herold M, Kemmler J, Mull B, Frick J, Huber C. Successful treatment of metastatic renal cell carcinoma with a biologic active dose of recombinant interferon gamma. J Clin Oncol. 1989;7:1875. doi: 10.1200/JCO.1989.7.12.1875. [DOI] [PubMed] [Google Scholar]
  • 6.Baniyas M, Garcia-Morales P, Bonifacino JS, Samelson LE, Klausner RD. Disulfide linkage of the zeta and eta chains of the T cells receptor. Possible identification of two structural classes of receptors. J Biol Chem. 1988;263:9874. [PubMed] [Google Scholar]
  • 7.Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumorassociated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA. 1989;86:7159. doi: 10.1073/pnas.86.18.7159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Benoist C, Mathis D. Generation of the alpha beta T cell repertoire. Curr Opin Immunol. 1992;4:156. doi: 10.1016/0952-7915(92)90005-y. [DOI] [PubMed] [Google Scholar]
  • 9.Berd D, Maguire HC, McCue P, Mastrangelo M. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol. 1990;8:1858. doi: 10.1200/JCO.1990.8.11.1858. [DOI] [PubMed] [Google Scholar]
  • 10.Bergmann L, Weidmann E, Mitrou PS, Runne U, Keiholz U, Bartsch HN, Frank CR. Interleukin 2 in combination with interferon alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study. Onkologie. 1990;13:137. doi: 10.1159/000216741. [DOI] [PubMed] [Google Scholar]
  • 11.Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS. Daily alternating administration of high-dose interferon alpha and interleukin 2 bolus infusion in metastatic renal cell cancer. A phase II study. Cancer. 1993;72:1733. doi: 10.1002/1097-0142(19930901)72:5<1733::aid-cncr2820720537>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  • 12.Berke G. T-cell mediated cytotoxicity. Curr Opin Immunol. 1991;3:320. doi: 10.1016/0952-7915(91)90031-u. [DOI] [PubMed] [Google Scholar]
  • 13.Berke G, Rosen D, Ronen D. Mechanism of lymphocyte-mediated cytolysis: functional cytolytic T cells lacking perforin and granzymes. Immunology. 1993;78:105. [PMC free article] [PubMed] [Google Scholar]
  • 14.Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T-cell recognition regions of class 1 histocompatibility antigens. Nature. 1987;332:512. doi: 10.1038/329512a0. [DOI] [PubMed] [Google Scholar]
  • 15.Boitel B, Ermonval M, Panina-Bordingnon P, Mariuzza RA, Lanzavecchia A, Acuto O. Preferential usage and lack of junctional sequence conservation among human T cell receptors specific for tetanus toxin-derived peptide. Evidence for a dominant role of a germline-encoded V region in antigen/major histocompatibility complex recognition. J Exp Med. 1992;175:765. doi: 10.1084/jem.175.3.765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Boon T. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer. 1993;54:177. doi: 10.1002/ijc.2910540202. [DOI] [PubMed] [Google Scholar]
  • 17.Brenner MC, Strominger JL, Krangel MS. The gamma/delta T cell receptor. Adv Immunol. 1992;51:85. [PubMed] [Google Scholar]
  • 18.Brocker EB, Kolde G, Steinhausen D, Peters A, Macher E. The pattern of the mononuclear infiltrate as a prognostic parameter in flat superficial spreading melanomas. J Cancer Res Clin Oncol. 1984;107:48. doi: 10.1007/BF00395490. [DOI] [PubMed] [Google Scholar]
  • 19.Carrel S, Isler P, Schreger M, Vacca A, Salvi S, Giuffre L, Madi PJ-P. Expression on human thymocytes of the idiotypic structures (Ti) from two leukemiz T cell lines. Jurkat and HPB-ALL. Eur J Immunol. 1986;16:649. doi: 10.1002/eji.1830160610. [DOI] [PubMed] [Google Scholar]
  • 20.Chatila T, Geha RS. Superantigens. Curr Opin Immunol. 1992;4:74. doi: 10.1016/0952-7915(92)90129-3. [DOI] [PubMed] [Google Scholar]
  • 21.Chen ME, Bander NH, Aulitzky W, Gastl GA. Variability in the T cell receptor V alpha usage in human renal cell carcinoma (abstract 2723) Proc Am Assoc Cancer Res. 1993;34:456. [Google Scholar]
  • 22.Choi YW, Kotzin B, Herron L, Callahan J, Marrack P, Kappler J. Interaction ofStaphylococcus aureus toxin “super-antigens” with human T cells. Proc Natl Acad Sci USA. 1989;86:8941. doi: 10.1073/pnas.86.22.8941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Choi YW, Herman A, DiGiusto D, Wade T, Marrack P, Kappler J. Residues of the variable region of the T cell receptor beta chain that interact withS. aureus toxin superantigens. Nature. 1990;346:471. doi: 10.1038/346471a0. [DOI] [PubMed] [Google Scholar]
  • 24.Choita C, Boswell DR, Lesk AM. The outline structure of the T cell receptor. EMBO J. 1988;7:3745. doi: 10.1002/j.1460-2075.1988.tb03258.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Chou L, Ashe S, Brady WA, Hellstrom J, Hellstrom KE, Linsley PS. Co-stimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71:1093. doi: 10.1016/s0092-8674(05)80059-5. [DOI] [PubMed] [Google Scholar]
  • 26.Chou T, Chang AE, Shu SY. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity. J Immunol. 1988;140:2453. [PubMed] [Google Scholar]
  • 27.Clevers H, Alacron B, Willeman T, Terhorst C. The T cell receptor/CD3 complex: A dynamic protein ensemble. Annu Rev Immunol. 1988;6:629. doi: 10.1146/annurev.iy.06.040188.003213. [DOI] [PubMed] [Google Scholar]
  • 28.Concannon P, Pickering LA, Kung P, Hood L. Diversity and structure of the human T cell receptor beta-chain variable region genes. Proc Natl Acad Sci USA. 1986;83:6598. doi: 10.1073/pnas.83.17.6598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Dahiya R, Kwak KS, Byrd JC, Ho S, Yoon WH, Kim YS. Mucin synthesis and expression in various human epithelial cancer cell lines that express the MUC-1 mucin gene. Cancer Res. 1993;53:1437. [PubMed] [Google Scholar]
  • 30.Damle NK, Doyle LV, Bradley EC. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol. 1986;137:2814. [PubMed] [Google Scholar]
  • 31.Darrow TL, Slingluff CL, Jr, Siegler HF. The role of HLA class I antigens in recognition of melanoma cells by tumorspecific cytotoxic T lymphocytes. J Immunol. 1989;142:3329. [PubMed] [Google Scholar]
  • 32.Davies TE, Martin A, Concepcion ES, Graves P, Cohen L, Ben-Nun A. Evidence of limited variability of antigen receptors on intrathyroidal T cells in autoimmune thyroid disease. N Engl J Med. 1991;325:238. doi: 10.1056/NEJM199107253250404. [DOI] [PubMed] [Google Scholar]
  • 33.Davis LS, Oppenheimer-Marks N, Bednarezyk JL, McIntyre BW, Lipsky PE. Fibronectin promotes proliferation of naive and memory T cells by signalling through VLA4 and VLA5 integrin molecules. J Immunol. 1990;145:785. [PubMed] [Google Scholar]
  • 34.Degiovanni G, Lahaye T, Herin M, Hainaut P, Boon T. Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones. Eur J Immunol. 1988;18:671. doi: 10.1002/eji.1830180503. [DOI] [PubMed] [Google Scholar]
  • 35.Depuis M, Schaerer E, Krause KH, Tschopp J. The calcium binding protein calreticulin is a major constituent of lytic granules in cytolytic T lymphocytes. J Exp Med. 1973;177:1. doi: 10.1084/jem.177.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Dohlsten M, Hedlund G, Kalland T. Staphylococcal-enterotoxin-dependent cell-mediated cytotoxicity. Immunol Today. 1991;12:147. doi: 10.1016/S0167-5699(05)80043-X. [DOI] [PubMed] [Google Scholar]
  • 37.Dyson PJ, Knight AM, Fairchild S, Simpson E, Tomonari K. Genes encoding ligands for deletion of V beta 11 T cells cosegregate with mammary tumor virus genomes. Nature. 1991;349:531. doi: 10.1038/349531a0. [DOI] [PubMed] [Google Scholar]
  • 38.Ferradini L, Roman-Roman S, Azocar J, Michalaki H, Triebel F, Hercend T. Studies on the human T cell receptor alpha beta variable region genes. II. Identification of four additional V beta subfamilies. Eur J Immunol. 1991;21:935. doi: 10.1002/eji.1830210412. [DOI] [PubMed] [Google Scholar]
  • 39.Ferradini L, Roman SR, Azocar J, Aviril MF, Viel S, Triebel F, Hercend T. Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis. Cancer Res. 1992;52:4649. [PubMed] [Google Scholar]
  • 40.Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend T. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. J Clin Invest. 1993;91:1183. doi: 10.1172/JCI116278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ferrini S, Miescher S, Zocchi MR, Von Fliedner V, Moretta A. Phenotypic and functional characterization of recombinant interleukin 2 (rIL-2)-induced act ivated killer cells: analysis at the population and clonal level. J Immunol. 1987;138:1297. [PubMed] [Google Scholar]
  • 42.Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, Bukowski R. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunol. 1992;11:1. doi: 10.1097/00002371-199201000-00001. [DOI] [PubMed] [Google Scholar]
  • 43.Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O'Shea JJ, Kudoh S, Klein E, Bukowski RM, Ochoa AC. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993;53:5613. [PubMed] [Google Scholar]
  • 44.Fisk B, Tucker SL, Pollack MS, Flytzanis CN, Ioannides CG. Characterization of T cell receptor V beta repertoire in ovarian tumor-infiltrating lymphocytes (abstract 2736) Proc Am Assoc Cancer Res. 1993;34:459. [Google Scholar]
  • 45.Fleischer B. Superantigens. Curr Opin Immunol. 1992;4:392. doi: 10.1016/s0952-7915(06)80028-2. [DOI] [PubMed] [Google Scholar]
  • 46.Fleischer B, Schrezenmeier H. T cell stimulation by staphylococcal enterotoxins. J Exp Med. 1988;167:1697. doi: 10.1084/jem.167.5.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Forster A, Huck S, Ghanem X, Lefranc MP, Rabbitts TH. New subgroups in the human T cell rearranging V gamma gene locus. EMBO J. 1987;6:1945. doi: 10.1002/j.1460-2075.1987.tb02456.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Frank SJ, Engel I, Rutledge TM, Letouneur F. Structure/function analysis of the invariant subunits of the t cell antigen receptor. Semin Immunol. 1991;3:299. [PubMed] [Google Scholar]
  • 49.Frankel WN, Rudy C, Coffin JM, Huber BT. Linkage of Mls genes to endogenous mammary tumor viruses of inbred mice. Nature. 1991;349:526. doi: 10.1038/349526a0. [DOI] [PubMed] [Google Scholar]
  • 50.Gansbacher B. Use of IL2 transduced tumor cells as a vaccine against cancer. Abstract. Proc Am Assoc Cancer Res. 1993;34:582. [Google Scholar]
  • 51.Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 1990;50:7820. [PubMed] [Google Scholar]
  • 52.Gansbacher B, Ziev K, Cravin K, Hantzopoulos PA, Bouchard B, Hougton A, Gilboa E, Golde D. Retroviral gene transfer induced constitutive expression of interleukin 2 or interferon-gamma in irradiated human melanoma cells. Blood. 1992;80:2817. [PubMed] [Google Scholar]
  • 53.Gastl G, Finnstad CL, Guarini A, Bosl G, Gilboa E, Bander HH, Gansbacher B. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res. 1992;52:6229. [PubMed] [Google Scholar]
  • 54.Gemlo BT, Palladino MA, Jr, Jaffe HS, Espevik TP, Rayner AA. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine activated killer cells. Cancer Res. 1988;48:5864. [PubMed] [Google Scholar]
  • 55.Geppert TD, Davis LS, Gur H, Wacholtz MC, Lipsky PE. Accessory cell signals involved in T cell activation. Immunol Rev. 1990;117:5. doi: 10.1111/j.1600-065x.1990.tb00566.x. [DOI] [PubMed] [Google Scholar]
  • 56.Gorga JC. Structural analysis of class II major histocompatibility complex proteins. Crit Rev Immunol. 1992;11:305. [PubMed] [Google Scholar]
  • 57.Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon. I. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine activated killer cell phenomenon. II. The precursor cells are serologically distinct from peripheral T lymphocytes, memory CTL and NK cells. J Exp Med. 1983;157:884. doi: 10.1084/jem.157.3.884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Haranaka K, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer. 1984;34:263. doi: 10.1002/ijc.2910340219. [DOI] [PubMed] [Google Scholar]
  • 60.Herrmann T, Romero P, Sartoris S, Paiola F, Accolla RS, Maryanski JL, MacDonald HR. Staphylococcal enterotoxin dependent lysis of MHC class II negative target cells by cytotoxic T lymphocytes. J Immunol. 1991;146:2504. [PubMed] [Google Scholar]
  • 61.Hersey P, Edwards A, Milton G, McCarthy WH. Relationship of cell-mediated cytotoxicity against melanoma cells: prognosis in melanoma patients. Br J Cancer. 1978;37:505. doi: 10.1038/bjc.1978.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Hui KM, Sim T, Foo TT, Oei A-A. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J Immunol. 1989;143:3835. [PubMed] [Google Scholar]
  • 63.Ioannides CG, Whiteside TL. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol. 1993;66:91. doi: 10.1006/clin.1993.1012. [DOI] [PubMed] [Google Scholar]
  • 64.Ioannides CG, Freedman RS. Selective usage of TCR V beta in tumor-specific CTL lines isolated from ovarian tumorassociated lymphocytes. Anticancer Res. 1991;11:1919. [PubMed] [Google Scholar]
  • 65.Ioannides CG, Freedman RS, Platsoucas CD, Rashed S, Kim YP. Cytotoxic T cell clones isolated from ovarian tumorinfiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol. 1991;146:1700. [PubMed] [Google Scholar]
  • 66.Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res. 1991;51:4257. [PubMed] [Google Scholar]
  • 67.Itoh K, Platsoucas CD, Balch CM. Autologous tumorspecific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med. 1988;168:1419. doi: 10.1084/jem.168.4.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Jerome KR, Barnd DL, Bendt KM, Bower CM, Taylor-Papadimitriou J, McKendzie IF, Bast RC, Jr, Finn OJ. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 1991;51:2908. [PubMed] [Google Scholar]
  • 69.Jerome KR, Bu D, Finn OJ. Expression of tumor-associated epitopes on Epstein-Barr virus-immortalized B-cells and Burkitt's lymphomas transfected with epithelial mucin complementary DNA. Cancer Res. 1992;52:5985. [PubMed] [Google Scholar]
  • 70.Jin YJ, Clayton LK, Howard FD, Koyasu S, Sich M, Steinbrich R, Tarr GE, Reinherz EL. Molecular cloning of the CD3 zeta subunit identifies a CD3 epsilon related product in thymus derived cells. Proc Natl Acad Sci USA. 1990;87:3319. doi: 10.1073/pnas.87.9.3319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Jotereau F, Pandolfino M-C, Boudart D, Diez E, Dreno B, Douillard JY, Muller JY, LeMevel B. High-fold expansion of human cytotoxic T-Lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother. 1991;10:405. doi: 10.1097/00002371-199112000-00003. [DOI] [PubMed] [Google Scholar]
  • 72.June CH. Signal transduction in T cells. Curr Opin Immunol. 1991;3:287. doi: 10.1016/0952-7915(91)90026-w. [DOI] [PubMed] [Google Scholar]
  • 73.June CH, Fletcher MC, Ledbetter JA, Schieven GL, Siegel JN, Phillips AF, Samelson LE. Inhibition of tyrosine phosphorylation prevents T cell receptor mediated signal transduction. Proc Natl Acad Sci USA. 1990;87:7722. doi: 10.1073/pnas.87.19.7722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Kan-Mitchell J, Huang XQ, Steinman L, Oskenberg JR, Harel W, Parker JW, Goedegebuute PS, Darrow TL, Mitchell MS. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother. 1993;37:15. doi: 10.1007/BF01516937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Kappler J, Herman A, Clements J, Marrack P. Mutations defining functional regions of the staphylococcal enterotoxin B. J Exp Med. 1992;175:387. doi: 10.1084/jem.175.2.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol. 1992;148:638. [PubMed] [Google Scholar]
  • 77.Kelly A, Powis SH, Kerr LA, Mockridge I, Elliott T, Bastin J, Uchanska-Ziegler B, Ziegler A, Trowsdale J, Townsend A. Assembly and function of the two ABC transporter proteins encoded in the human major histocompability complex. Nature. 1992;355:641. doi: 10.1038/355641a0. [DOI] [PubMed] [Google Scholar]
  • 78.Kemeny MM, Alava G, Oliver JM. Improving responses in hepatomas with circadian-patterened hepatic artery infusions of recombinant interleukin 2. J Immunother. 1992;12:219. doi: 10.1097/00002371-199211000-00001. [DOI] [PubMed] [Google Scholar]
  • 79.Kimura N, Toyonaga B, Yoshikai Y, Triebel F, Debre P, Minden MD, Mak TW. Sequences and diversity of the human T cell receptor beta chain variable region genes. J Exp Med. 1986;164:739. doi: 10.1084/jem.164.3.739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Knuth A, Danowski B, Oettgen HF, Old LG. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin-2-dependent T-cell cultures. Proc Natl Acad Sci USA. 1984;81:3511. doi: 10.1073/pnas.81.11.3511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Knuth A, Wolfel T, Meyer zum Buschenfelde K-H. Cellular and humoral immune responses against cancer: implications for cancer vaccines. Curr Opin Immunol. 1991;3:659. doi: 10.1016/0952-7915(91)90093-g. [DOI] [PubMed] [Google Scholar]
  • 82.Konig F, Amloy WL, Coligan JE. The implications of subunit interactions for the structure of the T cell receptor-CD3 complex. Eur J Immunol. 1990;20:299. doi: 10.1002/eji.1830200211. [DOI] [PubMed] [Google Scholar]
  • 83.Koo AS, Tso C-L, Shimabukuro T, Peyret SC, deKernion JB, Belldegrun A. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother. 1991;10:347. doi: 10.1097/00002371-199110000-00006. [DOI] [PubMed] [Google Scholar]
  • 84.Koyasu S, Lawton T, Novick D, Racny MA, Siliciano RF, Wallner BP, Reinherz EL. Role of interaction of CD2 molecules with lymphocyte function-associated antigen 3 in T cell recognition of normal antigen. Proc Natl Acad Sci USA. 1990;87:2603. doi: 10.1073/pnas.87.7.2603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ, Strauss HW. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1989;1:577. doi: 10.1016/s0140-6736(89)91609-7. [DOI] [PubMed] [Google Scholar]
  • 86.Kronenberg M, Siu G, Hood LE, Shastri N. The molecular genetics of the T cell antigen receptor and T cell antigen recognition. Annu Rev Immunol. 1986;4:529. doi: 10.1146/annurev.iy.04.040186.002525. [DOI] [PubMed] [Google Scholar]
  • 87.Lefranc MP. Organization of the human T cell receptor genes. Eur Cytokine Net. 1990;1:121. [PubMed] [Google Scholar]
  • 88.Lefranc MP, Forster A, Baer R, Stinson MA, Rabbitts TH. Diversity and rearrangement of the human T cell rearranging gamma genes: nine germline variable genes belonging to two subgroups. Cell. 1986;45:237. doi: 10.1016/0092-8674(86)90388-0. [DOI] [PubMed] [Google Scholar]
  • 89.Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 co-stimulates T cell proliferation and IL2 mRNA accumulation. J Exp Med. 1991;173:721. doi: 10.1084/jem.173.3.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Lotze MT (1994) Gene therapy of cancer: a pilot study of IL4 gene-modified tumor vaccines. Clinical protocol in progress. Pittsburgh Cancer Institute. (internal publication)
  • 91.Lotze MT, Finn OJ (1994) In vivo testing of the immune response to human breast, colon, and pancreatic tumor mucin. Clinical protocol in progress. Pittsburgh Cancer Institute, (internal publication)
  • 92.Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, Hercend T. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 1993;53:3569. [PubMed] [Google Scholar]
  • 93.Mantovani A. Tumor-associated macrophages. Curr Opin Immunol. 1990;2:689. doi: 10.1016/0952-7915(90)90031-b. [DOI] [PubMed] [Google Scholar]
  • 94.Marrack P, Kappler J. The T cell receptor. Science. 1987;238:1073. doi: 10.1126/science.3317824. [DOI] [PubMed] [Google Scholar]
  • 95.Miescher S, Whiteside TL, Carrel S, Von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986;136:1899. [PubMed] [Google Scholar]
  • 96.Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplators P, Liauzun P, Miloux B. Interleukin 13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362:248. doi: 10.1038/362248a0. [DOI] [PubMed] [Google Scholar]
  • 97.Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor bearing hosts. Science. 1992;258:1795. doi: 10.1126/science.1465616. [DOI] [PubMed] [Google Scholar]
  • 98.Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L. Active specific immunotherapy for melanoma. J Clin Oncol. 1990;8:856. doi: 10.1200/JCO.1990.8.5.856. [DOI] [PubMed] [Google Scholar]
  • 99.Miyatake SM, Hanada H, Yamashita J, Yamaski T, Ueda M, Namba Y, Hanaoka M. Induction of human gliomaspcific cytotoxic T lymphocyte lines by autologous tumor stimulation and interleukin 2. J Neurooncol. 1986;4:55. doi: 10.1007/BF02158003. [DOI] [PubMed] [Google Scholar]
  • 100.Morrissey PJ, Goodwin RG, Nordan RP, Anderson D, Grabstein KH, Cosman D, Sims J, Lupton S, Acres B, Reed SG. Recombinant interleukin 7, pre-B stimulatory factor, has costimulatory activity on purified mature T cells. J Exp Med. 1989;169:707. doi: 10.1084/jem.169.3.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Mortarini R, Belli F, Parmiani G, Anichini A. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL 1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations. Int J Cancer. 1990;45:334. doi: 10.1002/ijc.2910450221. [DOI] [PubMed] [Google Scholar]
  • 102.Mule JJ, McIntosh JK, Jablons DM, Rosenberg SA. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med. 1990;171:629. doi: 10.1084/jem.171.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Mullen CA, Coale MM, Levy AT, Stetler-Stevenson WG, Liotta LA, Brandt S, Blaese RM. Fibrosarcoma cells transduced with the IL6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res. 1992;52:6020. [PubMed] [Google Scholar]
  • 104.Mulligan RC. The basic science of gene therapy. Science. 1993;260:926. doi: 10.1126/science.8493530. [DOI] [PubMed] [Google Scholar]
  • 105.Mustelin T, Coggeshall KM, Isakov N, Altman A. T cell antigen receptor mediated activation of phospholipase C requires tyrosine phosphorylation. Science. 1990;247:1584. doi: 10.1126/science.2138816. [DOI] [PubMed] [Google Scholar]
  • 106.Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol. 1987;138:989. [PubMed] [Google Scholar]
  • 107.Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J-L, Vivier E, Anderson P, Kiessling R. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993;53:5610. [PubMed] [Google Scholar]
  • 108.Nitta T, Oksenberg JR, Rao NA, Steinman L. Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. Science. 1990;249:672. doi: 10.1126/science.2382141. [DOI] [PubMed] [Google Scholar]
  • 109.Nitta T, Sato K, Okumura K, Steinman L. An analysis of T-cell-receptor variable-region genes in tumor-infiltrating lymphocytes within malignant tumors. Int J Cancer. 1991;49:545. doi: 10.1002/ijc.2910490412. [DOI] [PubMed] [Google Scholar]
  • 110.Oksenberg JR, Stuart S, Begovich AB, Bell RB, Ehrlich HA, Steinman L, Bernard CCA. Limited heterogeneity of rearranged T-cell-receptor V alpha transcripts in brains of multiple sclerosis patients. Nature. 1990;345:344. doi: 10.1038/345344a0. [DOI] [PubMed] [Google Scholar]
  • 111.Paliard X, West SG, Lafferty JA, Clements JR, Kappler J, Marrack P, Kotzin BL. Evidence for the effects of a superantigen in rheumatoid arthritis. Science. 1991;253:325. doi: 10.1126/science.1857971. [DOI] [PubMed] [Google Scholar]
  • 112.Parkinson DR. Interleukin 2 in cancer therapy. Semin Oncol. 1988;15:10. [PubMed] [Google Scholar]
  • 113.Peoples G, Davey M, Schoof DD, Eberlein TJ. Selective usage of TCR V beta genes in ovarian-specific CTL (abstract 2910) Proc Am Assoc Cancer Res. 1993;34:488. [Google Scholar]
  • 114.Posnett DN, Schmelkin L, Bruton DA, August A, McGrath H, Mayer LF. T cell antigen receptor V gene usage increases in V beta+ T cells in Crohn's disease. J Clin Invest. 1990;85:1170. doi: 10.1172/JCI114634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Puisieux I, Favrot MC, Pannetier C, Guillet JG, Kourilsky P, Even J. Characterization of the TCR beta chain repertoire of melanoma TILs during immunotherapy VDJ rearrangement analysis (abstract 2905) Proc Am Assoc Cancer Res. 1993;34:487. [Google Scholar]
  • 116.Pullen AM, Wade T, Marrack P, Kapples J. Identification of the region of the T cell receptor beta chain that interacts with the selt superantigen Mls-la. Cell. 1990;61:1365. doi: 10.1016/0092-8674(90)90700-o. [DOI] [PubMed] [Google Scholar]
  • 117.Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 1993;53:83. [PubMed] [Google Scholar]
  • 118.Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987;166:991. doi: 10.1084/jem.166.4.991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Ransom JH, Pelle BA, Brandhorst J, Hanna MG., Jr HLA-DR and ICAM-I expression on vaccine tumor cells predict clinical response to a human colon carcinoma vaccine (abstract 2918) Proc Am Assoc Cancer Res. 1993;153:489. [Google Scholar]
  • 120.Restifo NP, Spiess PJ, Karp SE, Mule JJ, Rosenberg SA. A nonimmunologic sarcoma transduced with the cDNA for interferon-gamma elicits CD8+ T cells against the wild type tumor: correlation with antigen presentation capability. J Exp Med. 1992;175:1423. doi: 10.1084/jem.175.6.1423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Ritz J, Schmidt RE, Michon J, Hercend T, Schlossman ST. Characterization of functional surface structures on human natural killer cells. Adv Immunol. 1988;42:181. doi: 10.1016/s0065-2776(08)60845-7. [DOI] [PubMed] [Google Scholar]
  • 122.Roman-Roman S, Ferradini L, Azocar J, Genevee C, Hercend T, Triebel F. Studies on the human T cell receptor alpha beta variable region genes. I. Identification of 7 additional V alpha subfamilies and 14 J alpha gene segments. Eur J Immunol. 1991;21:927. doi: 10.1002/eji.1830210411. [DOI] [PubMed] [Google Scholar]
  • 123.Rosenberg SA. Cancer therapy with interleukin 2: immunologic manipulations can mediate the regression of cancer in humans. J Clin Oncol. 1988;6:403. doi: 10.1200/JCO.1988.6.3.403. [DOI] [PubMed] [Google Scholar]
  • 124.Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Lineban WM, Robertson CN, Lee RF, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high-dose interleukin 2 alone. N Engl J Med. 1987;316:889. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  • 125.Rosenberg SA, Spiess P, Lafreniere R. A new approach to adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  • 126.Rosenberg SA, Packard BS, Acbersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319:1676. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  • 127.Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE. Combination therapy with interleukin 2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989;7:1863. doi: 10.1200/JCO.1989.7.12.1863. [DOI] [PubMed] [Google Scholar]
  • 128.Rosenberg SA, Lotze MT, Young JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE, Steinberg SM. Prospective randomized trial of high-dose interleukin 2 alone or in combination with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85:622. doi: 10.1093/jnci/85.8.622. [DOI] [PubMed] [Google Scholar]
  • 129.Rothenberg EV. The development of functionally responsive T cells. Adv Immunol. 1992;51:85. doi: 10.1016/s0065-2776(08)60487-3. [DOI] [PubMed] [Google Scholar]
  • 130.Schuchter LM, Wohlganger JA, Fishman EK, MacDermoth ML, McGuire WP. Sequential chemotherapy and immunotherapy for the treatment of metastatic melanoma. J Immunother. 1992;12:272. doi: 10.1097/00002371-199211000-00008. [DOI] [PubMed] [Google Scholar]
  • 131.Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science. 1990;248:1349. doi: 10.1126/science.2113314. [DOI] [PubMed] [Google Scholar]
  • 132.Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol. 1991;146:3674. [PubMed] [Google Scholar]
  • 133.Schwartzentruber DJ, Solomon D, Rosenberg SA, Topalian SL. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J Immunother. 1992;12:1. doi: 10.1097/00002371-199207000-00001. [DOI] [PubMed] [Google Scholar]
  • 134.Sensi M, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, Nicolini G, Nicolini G, Herlyn M, Parmiani G, Anichini A. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clones. J Exp Med. 1993;178:1231. doi: 10.1084/jem.178.4.1231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Shimizu Y, van Seventer GA, Horgan KJ, Shaw S. Costimulation of proliferative responses of resting CD4+ cells by the interaction of VLA4 and VLA5 with fibronectin or VLA6 with laminin. J Immunol. 1990;145:59. [PubMed] [Google Scholar]
  • 136.Shimizu Y, Weidmann E, Iwatsuki S, Herberman RB, Whiteside TL. Characterization of human autotumor-reactive T cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Res. 1991;51:6153. [PubMed] [Google Scholar]
  • 137.Si L, Whiteside TL, Schade RR, Van Thiel DH. Lymphocyte subsets studied with monoclonal antibodies in liver tissues of patients with alcoholic liver disease. Alcoholism. Clin Exp Res. 1983;7:431. doi: 10.1111/j.1530-0277.1983.tb05501.x. [DOI] [PubMed] [Google Scholar]
  • 138.Sim GK, Yague J, Nelson J. Primary structure of the T cell receptor alpha-chain. Nature. 1984;312:771. doi: 10.1038/312771a0. [DOI] [PubMed] [Google Scholar]
  • 139.Sosman JA, Hank JA, Sondel PM. In vivo activation of lymphokine activated killer activity with interleukin 2: prospects for combination therapies. Semin Oncol. 1990;17:22. [PubMed] [Google Scholar]
  • 140.Spertim F, Spits H, Geha RS. Staphylococcal toxins deliver activation signals to human T cells via major histocompatibility class II molecules. Proc Natl Acad Sci USA. 1991;88:7533. doi: 10.1073/pnas.88.17.7533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141.Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst. 1987;79:1067. [PubMed] [Google Scholar]
  • 142.Spits H. Human T cell receptor gamma/delta+ T cells. Semin Immunol. 1991;3:119. [PubMed] [Google Scholar]
  • 143.Spits H, Yssel H, Takebc Y, Arai N, Yokota T, Lei F, Arai K, Banchereau J, DeVries JE. Recombinant interleukin 4 promotes the growth of human T cells. J Immunol. 1987;139:1142. [PubMed] [Google Scholar]
  • 144.Stevenson FK. Tumor vaccines. FASEB J. 1994;5:2250. doi: 10.1096/fasebj.5.9.1860616. [DOI] [PubMed] [Google Scholar]
  • 145.Storkus WJ, Lotze MT. Melanoma immunogenicity: melanoma cells present both endogenously, and exogenously, derived peptides to CD8+ cytolytic T cells (abstract) J Immunother. 1992;11:147. [Google Scholar]
  • 146.Tahery D, Ohmen J, Modlin R, Wyzykowski R, Sullivan L, Moy R. T cell receptor beta chain repertoire of tumor infiltrating lymphocytes in basal cell carcinoma (abstract 1874) Proc Am Assoc Cancer Res. 1992;33:314. [Google Scholar]
  • 147.Thompson CB, Lindstein T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH. CD28 activation pathway regulates the production of multiple T cell derived lymphokine/cytokines. Proc Natl Acad Sci USA. 1989;86:1333. doi: 10.1073/pnas.86.4.1333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148.Thor Straten P, Scholler J, Hon-Jansen K, Zenthen J (1994) Preferential usage of T-cell receptor alpha beta variable regions among tumor infiltrating lymphocytes in primary human malignant melanomas. Int J Cancer (in press) [DOI] [PubMed]
  • 149.Tilden AB, Itoh K, Balch CM. Human lymphokine activated killer (LAK) cells: identification of two types of effector cells. J Immunol. 1987;138:1068. [PubMed] [Google Scholar]
  • 150.Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol. 1988;6:839. doi: 10.1200/JCO.1988.6.5.839. [DOI] [PubMed] [Google Scholar]
  • 151.Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989;142:3714. [PubMed] [Google Scholar]
  • 152.Townsend A, Bodmer H. Antigen recognition by class I restricted T lymphocytes. Annu Rev. Immunol. 1989;7:601. doi: 10.1146/annurev.iy.07.040189.003125. [DOI] [PubMed] [Google Scholar]
  • 153.Toyonaga B, Yoshikai Y, Vadasz V, Chin B, Mak TW. Organization and sequences of the diversity, joining and constant region of the human T cell receptor beta chain. Proc Natl Acad Sci USA. 1985;82:8624. doi: 10.1073/pnas.82.24.8624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154.Traversari C, van der Bruggen P, Luesdier JF, Lurguin C, Chance P, Van Pel A, De Pleau E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE1 is recognized on HLA-A1 by CTL directed against tumor antigen M22-E. J Exp Med. 1992;176:1453. doi: 10.1084/jem.176.5.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 155.Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A. Sequences encoded in the class II region of the MHC related to the “ABC” superfamily of transporters. Nature. 1990;348:741. doi: 10.1038/348741a0. [DOI] [PubMed] [Google Scholar]
  • 156.Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD. Gamma interferon plays a key role in T cell induced tumor regression. Cancer Res. 1993;53:833. [PubMed] [Google Scholar]
  • 157.Uchiyama A, Hoon DS, Morisaki T, Kaneda Y, Yuzuki DH, Morton DL. Transfection of interleukin 2 gene in human melanoma cells augments cellular immune response. Cancer Res. 1993;53:949. [PubMed] [Google Scholar]
  • 158.Unanue ER. Antigen presenting function of the macrophage. Annu Rev Immunol. 1984;2:395. doi: 10.1146/annurev.iy.02.040184.002143. [DOI] [PubMed] [Google Scholar]
  • 159.Valteau-Couanet D, Carcelain G, Leboulaire C, Triebel F, Hercend T, Hartmann O. Analysis of T cell receptor (TCR) of tumor-infiltrating lymphocytes (TILs) in neoblastoma (NB) (abstract 2906) Proc. Am Assoc Cancer Res. 1993;34:487. [Google Scholar]
  • 160.Van den Eynde B, Lethe B, Van Pel A, De Plan E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med. 1991;173:1373. doi: 10.1084/jem.173.6.1373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 161.Van der Bruggen P, Traversari C, Chomez P, Lurquin C, de Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643. doi: 10.1126/science.1840703. [DOI] [PubMed] [Google Scholar]
  • 162.Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA 1 ligand, ICAM 1 provides an important constimulatory signal for T cell receptor mediated activation of resting T cells. J Immunol. 1990;144:4579. [PubMed] [Google Scholar]
  • 163.Van Seventer GA, Shimizu Y, Shaw S. Role of multiple accessory molecules in T cell activation. Curr Opin Immunol. 1991;3:294. doi: 10.1016/0952-7915(91)90027-x. [DOI] [PubMed] [Google Scholar]
  • 164.Velotti F, Cippitelli M, Palmieri G, Punturieri A, Stoppacciaro A, Cusumano G, Tubaro A, Ruco L, Santoni A. In vitro bladder cancer cells express interleukin 2 receptor (abstract 1793) Proc Am Assoc Cancer Res. 1992;33:301. [Google Scholar]
  • 165.Veltri RW, Rodman SM, Maxim PE, Baseler MW, Sprinkle PM. Immune complexes, serum proteins, cell-mediated immunity and immune regulation in patients with squamous cell carcinoma of the head and neck. Cancer. 1986;57:2295. doi: 10.1002/1097-0142(19860615)57:12<2295::aid-cncr2820571211>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  • 166.Viens P, Blaise D, Stoppa AM. Interleukin 2 in association with increasing doses of interferon gamma in patients with advanced cancer. J Immunother. 1992;11:218. doi: 10.1097/00002371-199204000-00009. [DOI] [PubMed] [Google Scholar]
  • 167.Vitolo D, Zerbe T, Kanbour A, Dahl C, herberman RB, Whiteside TL. Expression of mRNA for cytokines in tumor-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cancer. 1992;51:573. doi: 10.1002/ijc.2910510412. [DOI] [PubMed] [Google Scholar]
  • 168.Watanabe Y. Transfection of interferon gamma gene in animal tumors—a model for local cytokine production and tumor immunity. Semin Cancer Biol. 1993;3:43. [PubMed] [Google Scholar]
  • 169.Weidmann E, Bergmann L, Hechler P, Mitrou PS. Cytotoxic activity and phenotypic characteristics of lymphocyte aubsets after therapy of cancer patients with interleukin 2. Cancer Immunol Immunother. 1991;33:398. doi: 10.1007/BF01741601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170.Weidmann E, Bergmann L, Stock J, Kirsten R, Mitrou PS. Rapid cytokine release in cancer patients treated with interleukin 2. J Immunother. 1992;12:123. doi: 10.1097/00002371-199208000-00007. [DOI] [PubMed] [Google Scholar]
  • 171.Weidmann E, Elder EM, Herberman RB, Trucco M, Whiteside TL. The T-cell receptor beta chain variable region repertoire in fresh and cultured lymphocytes isolated from human malignant melanomas. In: Bergmann L, Mitrou PS, editors. Cytokines in cancer therapy. Contribution to oncology. Vol. 46. Germany: Karger; 1994. pp. 133–142. [Google Scholar]
  • 172.Weidmann E, Elder EM, Trucco M, Lotze MT, Whiteside TL. Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int J Cancer. 1993;54:383. doi: 10.1002/ijc.2910540306. [DOI] [PubMed] [Google Scholar]
  • 173.Weidmann E, Sacchi M, Plaisance S, Heo DS, Yasumura S, Lin WC, Johnson JT, Herberman RB, Azzarone B, Whiteside TL. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res. 1992;52:5963. [PubMed] [Google Scholar]
  • 174.Weidmann E, Whiteside TL, Giorda R, Herberman RB, Trucco M. The T cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res. 1992;52:5913. [PubMed] [Google Scholar]
  • 175.Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res. 1993;53:4745. [PubMed] [Google Scholar]
  • 176.Weiss A. Structure and function of the T cell antigen receptor. J Clin Invest. 1990;86:1015. doi: 10.1172/JCI114803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 177.Weissman AM, Hou D, Orloff DG, Modi WS, Seuane ZH, O'Brien SJ, Klausner RD. Molecular cloning and chromosomal localization of the human T cell receptor zeta chain: distinction from the molecular CD3 complex. Proc. Natl Acad Sci USA. 1988;85:9709. doi: 10.1073/pnas.85.24.9709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 178.West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]
  • 179.Whiteside TL. Tumor-infiltrating lymphocytes as antitumor effector cells. Biotherapy. 1992;5:47. doi: 10.1007/BF02194785. [DOI] [PubMed] [Google Scholar]
  • 180.Whiteside TL. Tumor-infiltrating lymphocytes in human malignancies. Austin. Tex: Landes; 1993. [Google Scholar]
  • 181.Wolfel T, Klehmann E, Muller C, schutt KH, Meyer zum Buschenfelde KH, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones: identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med. 1989;170:797. doi: 10.1084/jem.170.3.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182.Woodland DL, Happ MP, Golob KJ, Palmer E. An endogenous retrovirus mediating deletion of alpha beta T cells. Nature. 1991;349:529. doi: 10.1038/349529a0. [DOI] [PubMed] [Google Scholar]
  • 183.Yasumura S, Hirabayashi H, Schwartz DR, Toso JF, Johnson JT, Herberman RB, Whiteside TL. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res. 1993;53:1461. [PubMed] [Google Scholar]
  • 184.Yasumura S, Weidmann e, Hirabayashi H, Johnson JT, Herberman RB, Whiteside TL (1994) HLA restriction and T-cell receptor Vβ gene expression of cytotoxic T lymphocytes reactive with human squamous cell carcinoma of the head and neck. Int J Cancer (in press) [DOI] [PubMed]
  • 185.Yoshikai Y, Anatoniou D, Clark SP, Yanagi Y, Sangster R, Van den Elsen P, Terhorst C, Mak TW. Sequence and expression of transcripts of the human T cell receptor beta chain genes. Nature. 1984;312:521. doi: 10.1038/312521a0. [DOI] [PubMed] [Google Scholar]
  • 185.Zakut R, Topalian SL, Kawakami Y, Mancini M, Eliyahu S, Rosenberg SA. Differential expression of MAGE-1, -2 and-3 messenger RNA in transformed and normal human cells. Cancer Res. 1993;53:5. [PubMed] [Google Scholar]
  • 187.Zipfel PF, Irving SG, Kelly K, Siebenlist U. Complexity of the primary genetic response to mitogenic activation of human T cell. Mol Cell Biol. 1989;9:1041. doi: 10.1128/mcb.9.3.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 188.Zocchi MR, Poggi A, Crosti F, Tongiani S, Rugarli C. Signalling in human tumor infiltrating lymphocytes: the CD28 molecule is functional and is physically associated with CD45RO molecule. Eur J Cancer. 1992;28A:749. doi: 10.1016/0959-8049(92)90108-e. [DOI] [PubMed] [Google Scholar]
  • 189.Zychlinski A, Joag S, Young JD-E. Cytolytic mechanisms of the immune system. Curr Opin Immunol. 1988;1:63. doi: 10.1016/0952-7915(88)90052-0. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES